Hong Kong · Delayed Price · Currency is HKD Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of HKD 10.63 billion. The enterprise value is 8.01 billion.
| Market Cap | 10.63B |
| Enterprise Value | 8.01B |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascletis Pharma has 1.06 billion shares outstanding. The number of shares has increased by 3.75% in one year.
| Current Share Class | 1.06B |
| Shares Outstanding | 1.06B |
| Shares Change (YoY) | +3.75% |
| Shares Change (QoQ) | +5.83% |
| Owned by Insiders (%) | 51.84% |
| Owned by Institutions (%) | 3.47% |
| Float | 214.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9,719.92 |
| PB Ratio | 4.05 |
| P/TBV Ratio | 4.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.92 |
| Quick Ratio | 12.89 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -4,628.49 |
Financial Efficiency
Return on equity (ROE) is -28.59% and return on invested capital (ROIC) is -21.07%.
| Return on Equity (ROE) | -28.59% |
| Return on Assets (ROA) | -19.64% |
| Return on Invested Capital (ROIC) | -21.07% |
| Return on Capital Employed (ROCE) | -30.73% |
| Weighted Average Cost of Capital (WACC) | 6.41% |
| Revenue Per Employee | 5,038 |
| Profits Per Employee | -3.15M |
| Employee Count | 202 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.18 |
Taxes
In the past 12 months, Ascletis Pharma has paid 697,301 in taxes.
| Income Tax | 697,301 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.70% in the last 52 weeks. The beta is 0.39, so Ascletis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -28.70% |
| 50-Day Moving Average | 10.04 |
| 200-Day Moving Average | 13.24 |
| Relative Strength Index (RSI) | 49.69 |
| Average Volume (20 Days) | 2,135,030 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of HKD 1.09 million and -682.99 million in losses. Loss per share was -0.68.
| Revenue | 1.09M |
| Gross Profit | 468,716 |
| Operating Income | -806.86M |
| Pretax Income | -682.29M |
| Net Income | -682.99M |
| EBITDA | -793.14M |
| EBIT | -806.86M |
| Loss Per Share | -0.68 |
Balance Sheet
The company has 2.62 billion in cash and 4.31 million in debt, with a net cash position of 2.62 billion or 2.48 per share.
| Cash & Cash Equivalents | 2.62B |
| Total Debt | 4.31M |
| Net Cash | 2.62B |
| Net Cash Per Share | 2.48 |
| Equity (Book Value) | 2.62B |
| Book Value Per Share | 2.52 |
| Working Capital | 2.44B |
Cash Flow
In the last 12 months, operating cash flow was -659.36 million and capital expenditures -3.32 million, giving a free cash flow of -662.68 million.
| Operating Cash Flow | -659.36M |
| Capital Expenditures | -3.32M |
| Depreciation & Amortization | 13.89M |
| Net Borrowing | -7.55M |
| Free Cash Flow | -662.68M |
| FCF Per Share | -0.63 |
Margins
| Gross Margin | 42.87% |
| Operating Margin | -73,801.50% |
| Pretax Margin | -62,407.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.75% |
| Shareholder Yield | -3.75% |
| Earnings Yield | -6.43% |
| FCF Yield | -6.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Ascletis Pharma is 22.46, which is 129.42% higher than the current price. The consensus rating is "Buy".
| Price Target | 22.46 |
| Price Target Difference | 129.42% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 361.19% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |